NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The Guide to Clinical Preventive Services 2014: Recommendations of the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 May.
The Guide to Clinical Preventive Services 2014: Recommendations of the U.S. Preventive Services Task Force.
Show details| Title | Screening for Developmental Dysplasia of the Hip |
|---|---|
| Population | Infants who do not have obvious hip dislocations or other abnormalities evident without screening |
| Recommendation | No recommendation. Grade: I (Insufficient Evidence) |
| Risk Assessment | Risk factors for developmental dysplasia of the hip include female sex, family history, breech positioning, and in utero postural deformities. However, the majority of cases of developmental dysplasia of the hip have no identifiable risk factors. |
|---|---|
| Screening Tests | Screening tests for developmental dysplasia of the hip have limited accuracy. The most common methods of screening are serial physical examinations of the hip and lower extremities, using the Barlow and Ortolani procedures, and ultrasonography. |
| Interventions | Treatments for developmental dysplasia of the hip include both nonsurgical and surgical options. Nonsurgical treatment with abduction devices is used as early treatment and includes the commonly prescribed Pavlik method. Surgical intervention is used when the dysplasia is severe or diagnosed late, or after an unsuccessful trial of nonsurgical treatment. Avascular necrosis of the hip is the most common and most severe potential harm of both surgical and nonsurgical interventions, and can result in growth arrest of the hip and eventual joint destruction, with significant disability. |
| Balance of Benefits and Harms | The USPSTF was unable to assess the balance of benefits and harms of screening for developmental dysplasia of the hip due to insufficient evidence. There are concerns about the potential harms associated with treatment of infants identified by routine screening. |
| Other Relevant USPSTF Recommendations | The USPSTF has made recommendations on screening for hyperbilirubinemia, phenylketonuria, sickle cell disease, congenital hypothyroidism, and hearing loss in newborns. These recommendations are available at http://www |
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to http://www
.uspreventiveservicestaskforce.org/.
- [Table, Developmental Dysplasia of the Hip]. - The Guide to Clinical Preventive ...[Table, Developmental Dysplasia of the Hip]. - The Guide to Clinical Preventive Services 2014
- MAG: Candidatus Shapirobacteria bacterium CG10_big_fil_rev_8_21_14_0_10_48_15 CG...MAG: Candidatus Shapirobacteria bacterium CG10_big_fil_rev_8_21_14_0_10_48_15 CG10_8_21_14_0.10_scaffold_1056_c, whole genome shotgun sequencegi|1279228884|gb|PFEM01000008.1||gn :PFEM01|CG10_8_21_14_0.10_scaffold_1056_cNucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...